Prognosis
Controversial New Stem Cell Therapy Targets Spinal-Cord Injuries
- Nipro’s treatment released under Japan’s sped-up approvals
- Questions remain over effectiveness, clinical-trial process
This article is for subscribers only.
For the first time ever, patients with spinal-cord injuries will have access to stem-cell treatments, thanks to a controversial new therapy being offered in Japan starting this month.
Stemirac, developed by Nipro Corp. and Sapporo Medical University, aims to solve one of the most difficult quandaries in medicine: letting paraplegics and quadriplegics move again. The treatment, which costs about 15 million yen ($135,000), will be available for as many as 100 patients a year under a sped-up process that aims to get more drugs onto the market without rigorous clinical testing. Initial trials have already shown some success.